Report Detail

TABLE OF CONTENTS

    1. Introduction

    • 1.1 Scope Of The Study
    • 1.2 The Insight Partners Research Report Guidance

    2. Europe Smart Inhalers Market - Key Takeaways

      3. Europe Smart Inhalers Market - Market Landscape

      • 3.1 Overview
      • 3.2 Market Segmentation
        • 3.2.1 Europe Smart Inhalers Market - By Product
        • 3.2.2 Europe Smart Inhalers Market - By Disorder
        • 3.2.3 Europe Smart Inhalers Market - By End User
        • 3.2.4 Europe Smart Inhalers Market - By Europe Region
      • 3.3 Pest Analysis

      4. Europe Smart Inhalers Market - Key Market Dynamics

      • 4.1 Key Market Drivers
        • 4.1.1 Increasing Levels of Air Pollution as well as Rise in the Smoking Habits
        • 4.1.2 Rising Prevalence of Asthma and COPD Across the Europe
        • 4.1.3 Growing Geriatric Population
      • 4.2 Key Market Restraints
        • 4.2.1 Risks Associated with Cyber Threats
        • 4.2.2 Limited Knowledge Regarding the Use of Smart Inhalers
      • 4.3 Key Market Opportunity
        • 4.3.1 Growth in the Global Healthcare Market
      • 4.4 Future Trend
        • 4.4.1 Increasing Acceptance of Mobile Health Technology
      • 4.5 Impact Analysis

      5. Smart Inhalers Market - Europe Analysis

      • 5.1 Europe Smart Inhalers Market Revenue Forecasts And Analysis
      • 5.2 Performance Of Key Players

      6. Smart Inhalers Market Analysis And Forecasts To 2027 - Product

      • 6.1 Overview
      • 6.2 Europe Smart Inhalers Market Share By Product 2018 & 2027 (%)
      • 6.3 Inhalers Market
        • 6.3.1 Overview
        • 6.3.2 Inhalers Market Revenue and Forecast to 2027 (US$ Mn)
      • 6.4 Nebulizers Market
        • 6.4.1 Overview
        • 6.4.2 Nebulizers Market Revenue and Forecast to 2027 (US$ Mn)

      7. Smart Inhalers Market Analysis And Forecasts To 2027 - Disorder

      • 7.1 Overview
      • 7.2 Europe Smart Inhalers Market Share By Application 2018 & 2027 (%)
      • 7.3 Asthma Diabetes
        • 7.3.1 Overview
        • 7.3.2 Asthma Market Revenue and Forecast to 2027 (US$ Mn)
      • 7.4 Chronic Obstructive Pulmonary Disease Market
        • 7.4.1 Overview
        • 7.4.2 Chronic Obstructive Pulmonary Disease Market Revenue and Forecast to 2027 (US$ Mn)

      8. Smart Inhalers Market Analysis And Forecasts To 2027 -End User

      • 8.1 Overview
      • 8.2 Europe Smart Inhalers Market Share By End User 2018 & 2027 (%)
      • 8.3 Hospitals & Clinics Market
        • 8.3.1 Overview
        • 8.3.2 Hospitals & Clinics Market Revenue and Forecast to 2027 (US$ Mn)
      • 8.4 Home Care Settings Market
        • 8.4.1 Overview
        • 8.4.2 Home-Care Settings Market Revenue and Forecast to 2027 (US$ Mn)

      9. Smart Inhalers Market Revenue And Forecasts To 2027 - Europe Analysis

      • 9.1 Europe Smart Inhalers Market Revenue And Forecasts To 2027
        • 9.1.1 Europe Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
        • 9.1.2 Europe Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
        • 9.1.3 Europe Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
        • 9.1.4 Europe Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.1.5 Europe Smart Inhalers Market Revenue And Forecasts to 2027, By Country (%)
        • 9.1.6 UK Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.6.1 UK Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.6.2 UK Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
          • 9.1.6.3 UK Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
          • 9.1.6.4 UK Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.1.7 Germany Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.7.1 Germany Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.7.2 Germany Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
          • 9.1.7.3 Germany Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
          • 9.1.7.4 Germany Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.1.8 France Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.8.1 France Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.8.2 France Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
          • 9.1.8.3 France Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
          • 9.1.8.4 France Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.1.9 Italy Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.9.1 Italy Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.9.2 Italy Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
          • 9.1.9.3 Italy Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
          • 9.1.9.4 Italy Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.1.10 Spain Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.10.1 Spain Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.10.2 Spain Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
          • 9.1.10.3 Spain Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
          • 9.1.10.4 Spain Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)

        10. Smart Inhalers Market- Industry Landscape

        • 10.1 Overview
        • 10.2 Comparative Company Analysis
        • 10.3 Growth Strategies Done By The Companies In The Market, (%)
        • 10.4 Organic Developments
          • 10.4.1 Overview
        • 10.5 Inorganic Developments
          • 10.5.1 Overview

        11. Smart Inhalers Market-Key Company Profiles

        • 11.1 Glaxosmithkline Plc.
          • 11.1.1 Key Facts
          • 11.1.2 Business Description
          • 11.1.3 Financial Overview
          • 11.1.4 Product Portfolio
          • 11.1.5 SWOT Analysis
          • 11.1.6 Key Developments
        • 11.2 Adherium Limited
          • 11.2.1 Key Facts
          • 11.2.2 Business Description
          • 11.2.3 Financial Overview
          • 11.2.4 Product Portfolio
          • 11.2.5 SWOT Analysis
          • 11.2.6 Key Developments
        • 11.3 Novartis AG
          • 11.3.1 Key Facts
          • 11.3.2 Business Description
          • 11.3.3 Financial Overview
          • 11.3.4 Product Portfolio
          • 11.3.5 SWOT Analysis
          • 11.3.6 Key Developments
        • 11.4 Vectura Group Plc
          • 11.4.1 Key Facts
          • 11.4.2 Business Description
          • 11.4.3 Financial Overview
          • 11.4.1 Product Portfolio
          • 11.4.2 SWOT Analysis
          • 11.4.3 Key Developments
        • 11.5 Cohero Health, Inc.
          • 11.5.1 Key Facts
          • 11.5.2 Business Description
          • 11.5.3 Financial Overview
          • 11.5.4 Product Portfolio
          • 11.5.5 SWOT Analysis
          • 11.5.6 Key Developments
        • 11.6 Crux Product Design Ltd
          • 11.6.1 Key Facts
          • 11.6.2 Business Description
          • 11.6.3 Financial Information
          • 11.6.4 Product Portfolio
          • 11.6.5 SWOT Analysis
          • 11.6.6 Key Developments
        • 11.7 Findair Sp. Z O. O.
          • 11.7.1 Key Facts
          • 11.7.2 Business Description
          • 11.7.3 Financial Overview
          • 11.7.4 Product Portfolio
          • 11.7.5 SWOT Analysis
          • 11.7.6 Key Developments
        • 11.8 Teva Pharmaceutical Industries Ltd.
          • 11.8.1 Key Facts
          • 11.8.2 Business Description
          • 11.8.3 Financial Overview
          • 11.8.4 Product Portfolio
          • 11.8.5 SWOT Analysis
          • 11.8.6 Key Developments
        • 11.9 3M
          • 11.9.1 Key Facts
          • 11.9.2 Business Description
          • 11.9.3 Financial Overview
          • 11.9.4 Product Portfolio
          • 11.9.5 SWOT Analysis
          • 11.9.6 Key Developments
        • 11.10 Amiko Digital Health Limited
          • 11.10.1 Key Facts
          • 11.10.2 Business Description
          • 11.10.3 Financial Overview
          • 11.10.4 Product Portfolio
          • 11.10.5 SWOT Analysis
          • 11.10.6 Key Developments

        12. Appendix

        • 12.1 About The Insight Partners

      The Europe smart inhalers market is expected to reach US$ 2,129.61 Mn in 2027 from US$ 302.40 Mn in 2018. The market is estimated to grow with a CAGR of 24.9% from 2019-2027.
      The growth of the smart inhalers market is primarily attributed to the growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition as well as the presence of supportive associations in the region. However, risks associated with cyber threats with smart inhalers are likely to pose a negative impact on the market growth. On the other hand, development of growth in the Europe healthcare market is likely to have a positive impact on the growth of the Europe smart inhalers market in the coming years.
      With rapid urbanization there has been growth in various adverse factors that have led to the growth of respiratory diseases across the Europe. Some of the factors leading to growth in the number of asthma and COPD cases across the Europe are rise in air pollution levels and increasing smoking habits.
      The rise in air pollution levels has been a matter of rising concern in developed as well as developing economies. As per data published by the World Health Organization (WHO) released during May 2018, 9 out of 10 individuals are believed to breathe air containing high levels of pollutants. Data published by WHO reveals that approximately 7 million people die every year due to exposure to fine particles present in polluted air, which penetrate deep into lungs and the cardiovascular system. This leads to various diseases such as lung cancer, pneumonia, chronic obstructive pulmonary diseases and respiratory infections, among others. Studies reveal, above 90% of air pollution-related deaths worldwide occur in low- and middle-income countries of the Eastern Mediterranean, European regions. According to world health organization (WHO), about 21,000 premature deaths per year in European region because of air pollution like Ozone pollution courses breathe difficulties, triggers asthma symptoms, and causes lung and heart diseases. Additionally increasing indirect effects of air pollution like growing climate change, because of transport is the fastest growing source of fossil-fuel emissions of carbon dioxide (CO2) which is a largest contributor of the climate change. As per data published by World Health Organization (WHO) Some 40 million people in the 115 largest cities in the European Union (EU) are exposed to air exceeding WHO air quality guideline values for at least one pollutant. Children that live close by the traffic of heavy duty vehicle have a high risk of respiratory then those living near less congested streets. Hence, the rising levels of air pollution coupled is anticipated to drive the demand for smart inhalers market during the forecast period.
      In 2018, the inhalers segment held a largest market share of the smart inhalers market, by product. The inhalers is expected to dominate its market share in 2027 owing to the increasing mortality rate of asthma. The inhalers segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.
      Home-care setting segment a largest market share of the smart inhalers market, by end user in 2018. This segment is also expected to dominate the market in 2027. As smart inhaler devices are connected digitally, enabling the patients to get advice from their physicians, even when situated far away. Home-care setting segment is also expected to grow at the fastest growth rate during the forecast period, 2019 to 2027.
      Some of the major primary and secondary sources for smart inhalers included in the report are, GlaxoSmithKline plc, Adherium Ltd., Vectura Group plc, Novartis AG, Findair Sp. z o. o., Cohero Health, Crux Product Design Ltd, Teva Pharmaceuticals, 3M, Amiko Digital Health Limited, and others.


      Summary:
      Get latest Market Research Reports on Europe Smart Inhalers. Industry analysis & Market Report on Europe Smart Inhalers is a syndicated market report, published as Europe Smart Inhalers Market to 2027 - Regional Analysis and Forecasts by Product (Nebulizers and Inhalers); Disorder (Chronic Obstructive Pulmonary Disease (COPD), and Asthma); End User (Home-Care Settings and Hospitals & Clinics), and Country. It is complete Research Study and Industry Analysis of Europe Smart Inhalers market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,000.00
      $4,000.00
      $5,000.00
      2,328.58
      3,104.77
      3,880.97
      2,720.05
      3,626.73
      4,533.42
      326,007.00
      434,676.00
      543,345.00
      215,395.20
      287,193.60
      358,992.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report